Home

Johnson & Johnson (JNJ)

153.58
+1.15 (0.75%)
NYSE · Last Trade: May 30th, 12:15 AM EDT
QuoteNewsPress ReleasesChartHistoricalFAQAboutCompetitors

Detailed Quote

Previous Close152.43
Open151.75
Bid152.00
Ask153.95
Day's Range151.56 - 154.04
52 Week Range140.68 - 169.99
Volume6,811,016
Market Cap403.71B
PE Ratio (TTM)-
EPS (TTM)-
Dividend & Yield4.960 (3.23%)
1 Month Average Volume7,855,327

Chart

About Johnson & Johnson (JNJ)

Johnson & Johnson is a multinational corporation engaged in the development, manufacturing, and marketing of a wide range of healthcare products. The company operates through three primary segments: pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for its commitment to innovation in healthcare, producing a diverse array of products that include prescription medications for various diseases, sophisticated medical devices for surgical procedures, and widely recognized consumer brands for personal care and wellness. With a focus on improving health outcomes, the company aims to address the evolving needs of patients and consumers around the world. Read More

News & Press Releases

3 Elite High-Yield Dividend Stocks Down 8% to 27% That Have Hiked Their Payouts for More than 50 Years in a Rowfool.com
Via The Motley Fool · May 29, 2025
Michael Mahoney Turned Boston Scientific Into A Medical Tech Empireinvestors.com
Michael Mahoney's grandfather was a cardiac surgeon — so his first career plan was to become a doctor. Mahoney didn't give up — he adjusted.
Via Investor's Business Daily · May 29, 2025
Johnson & Johnson to Host Investor Conference Call on Second-Quarter Results
Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Wednesday, July 16th to review second-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Darren Snellgrove, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executive team.
By Johnson & Johnson · Via Business Wire · May 28, 2025
P/E Ratio Insights for Johnson & Johnsonbenzinga.com
Via Benzinga · May 28, 2025
Why Is Teva Stock Trading Higher On Tuesday?benzinga.com
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design.
Via Benzinga · May 27, 2025
Why Dan Loeb Just Made Kenvue One Of His Top Holdingsbenzinga.com
Activist investor Dan Loeb's Third Point LLC acquired a significant stake in consumer health company Kenvue Inc. in Q1 2025.
Via Benzinga · May 27, 2025
1 Top Dividend Stock to Buy for a Lifetime of Passive Incomefool.com
Via The Motley Fool · May 27, 2025
Johnson & Johnson (NYSE:JNJ) – A Reliable Dividend Stock Worth Consideringchartmill.com
Johnson & Johnson (NYSE:JNJ) offers a strong dividend yield, consistent growth, and solid profitability, making it a compelling choice for income investors.
Via Chartmill · May 26, 2025
Investing for Passive Income? Here's What History Says About the Stability of Dividend King Stocks.fool.com
Via The Motley Fool · May 25, 2025
Generating Passive Income: 3 Top Dow Dividend Stocks to Buy for 2025 and Beyondfool.com
Via The Motley Fool · May 24, 2025
Elon Musk Commits to Tesla. Is That a Good Thing?fool.com
Via The Motley Fool · May 23, 2025
Value Investing Is Not Dead - It Just Got Smarterbenzinga.com
Via Benzinga · May 23, 2025
FDA Panel Reiterates the Cancer Risks of Talc
A panel of medical experts convened by the U.S. Food & Drug Administration urged the agency to study and adopt new standards to prohibit the use of talc in consumer products such as gum, candy, rice and pharmaceuticals.
By Beasley Allen Law Firm · Via Business Wire · May 23, 2025
This Healthy High-Yielding Dividend Stock Just Increased Its Payment for the 48th Year in a Rowfool.com
Via The Motley Fool · May 23, 2025
3 Buy-and-Hold Stocks Long-Term Investors Can Love in Any Market
For buy-and-hold investors looking for some quality names to navigate a turbulent market, here are three stocks to consider
Via MarketBeat · May 22, 2025
Johnson & Johnson to Participate in the Bernstein’s 41st Annual Strategic Decisions Conference
Johnson & Johnson (NYSE: JNJ) will present at the Bernstein’s 41st Annual Strategic Decisions Conference on Wednesday, May 28th, 2025. Management will participate in a Fireside Chat at 9:00 a.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · May 21, 2025
Apple, Nvidia, GM: CEOs Are Talking About Being American-Made Againbenzinga.com
US companies are reshoring manufacturing operations & investing billions in the country, led by Apple & Nvidia for tech, J&J & Eli Lilly for healthcare, Anheuser-Busch for beer, & Cra-Z-Art for toys. Detroit & beyond are benefiting from this trend.
Via Benzinga · May 20, 2025
Market Whales and Their Recent Bets on JNJ Optionsbenzinga.com
Via Benzinga · May 19, 2025
Meet the Warren Buffett Investment That's Gained 5,502,284% and Looks Set to Soar Even Higherfool.com
Warren Buffett has had a lot of successful investments, but one in particular has crushed the stock market time and again.
Via The Motley Fool · May 18, 2025
3 Magnificent Stocks That Are Passive Income Machinesfool.com
Via The Motley Fool · May 17, 2025
US-China Trade Truce, Trump's Middle East Deals Spark Wall Street Rally: This Week In Marketsbenzinga.com
U.S. and China cut tariffs by 115 points, sparking a stock rally and improving trade outlook. Trump secures $2 trillion in Gulf deals.
Via Benzinga · May 16, 2025
Nachawati Law Group Files New Ovarian Cancer Lawsuits Against Johnson & Johnson After Latest Bankruptcy Ploy Fails
Following a third failed bankruptcy maneuver by Johnson & Johnson (NYSE: JNJ), trial lawyers with Dallas-based Nachawati Law Group have filed three new lawsuits on behalf of women who developed cancer after prolonged use of the company’s talc-based products.
By Nachawati Law Group · Via Business Wire · May 15, 2025
Why Pfizer Is Poised For A Strong Comeback: My Top Pick For 2025benzinga.com
For investors willing to look beyond the current negative sentiment, Pfizer at today's prices represents a rare buying opportunity.
Via Benzinga · May 15, 2025
Jim Cramer Says Even 'Safety' Stocks Look Risky, Warns Of 'Wild Card' In Washington And Rising Treasury Yields As Reasons To Stay Away From Sure Betsbenzinga.com
Rising bond yields and uncertain politics make 'safety' stocks less appealing, says Jim Cramer. Even Procter & Gamble and Johnson & Johnson suddenly feel shaky to the market guru.
Via Benzinga · May 15, 2025
Johnson & Johnson to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th, 2025. Management will participate in a Fireside Chat at 3:20 p.m. Eastern Time.
By Johnson & Johnson · Via Business Wire · May 14, 2025